Treatment of Feline Degenerative Joint Disease

**PROFILE**

**Definition**
Degenerative joint disease (DJD) is a term that loosely encompasses various arthropathies, including:
- Osteoarthritis (OA)—disease of synovial joints characterized by loss of articular cartilage, osteophyte formation, bone remodeling, and inflammation
- Spondylosis deformans—disease involving fibrocartilagenous intervertebral joints of the spine characterized by development of bony spurs.

For the purposes of this article, all forms will be called DJD.

**DIAGNOSIS**

**Definitive Diagnosis**
For conclusive proof of osteoarthritis, look for radiographic signs supportive of the loss of articular cartilage, osteophyte formation, bone remodeling, and inflammation. Cytology of joint fluid shows increased inflammatory cell counts, increased protein levels, and decreased viscosity of fluid. Spondylosis deformans is diagnosed radiographically by identifying bony spurs of the fibrocartilagenous intervertebral joints of the spine.

**TREATMENT**

**Inpatient/Outpatient**
While alleviating chronic pain is an outpatient process, there may be some procedures (eg, fluid therapy) that require inpatient care. Given that many cats with DJD are elderly, concurrent conditions may need to be identified before treatment begins.

**Medical**
Most care will be medical (see Medications and also Table).

**Surgical**
Surgery is rarely recommended; inflammation resulting from healing, as well as the inherent degenerative process, will be present and progress postoperatively. In some cases, however, total hip replacement or femoral head excision is recommended.

**Activity**
Hips and elbows are the most commonly affected joints. Patients with hip (or stifle) involvement will have most difficulty jumping and climbing up, while those with elbow (or shoulder) disease will find downward movement more problematic. Commercially available stairs and ramps help bridge heights such as floor to bed or sofa.

**Nutritional Aspects**
There are now 2 diets designed for cats to help reduce the clinical signs of joint disease and improve mobility (Prescription Diet j/d Feline, hillsvet.com, and Medi-Cal Feline Mobility Support, royalcanin.us). Weight loss should be encouraged in obese animals to reduce the pressure on joints. The addition of omega 3 fatty acids may be beneficial by blocking the production of prostaglandins from arachidonic acid in the

---

See April 2009, page 51, for a complete discussion on diagnosing feline degenerative joint disease.
inflammatory cascade. However, because supplements containing fish oils may increase bleeding time, they should be used with caution in animals with known clotting defects.

**Alternative Therapies**

**Disease-Modifying Osteoarthritic Agents**

One approach to treatment of joint disease—slowing the progression of cartilage degradation as well as promoting rebuilding of healthy matrix—has received a lot of attention and research in the past decade. Products have been developed that, in research (mainly in vitro) in humans and dogs, have been shown to be beneficial in enhancing hyaluronic acid production, inhibiting catabolic enzymes in osteoarthritic joints, and encouraging normalization of the synovial fluid and joint cartilage matrix.

**Glucosamine** reportedly affects the synthesis of glycosaminoglycans as well as the production of hyaluronic acid by synoviocytes and may normalize cartilage metabolism. Glucosamine stimulates synthesis of prostaglandin and collagen by chondrocytes and fibroblasts, suggesting that it upregulates synthesis.

**Chondroitin sulfate** (CS) is the predominant glycosaminoglycan found in articular cartilage and can be purified from bovine, whale, and shark cartilage sources. Bioavailability studies in rats, dogs, and humans have shown a 70% absorption rate following oral administration and suggest that CS reaches the synovial fluid and articular cartilage. In humans with OA, treatment with CS increased hyaluronate concentrations and synovial fluid viscosity with a concurrent decrease in collagenolytic activity.

Oral preparations containing these agents (ie, glucosamine/chondroitin sulfate; Cosequin, nutramaxlabs.com) and parenterally injected preparations (polysulfated glucosaminoglycan; Adequan, novartis.com) have been shown to have therapeutic benefit in in vivo studies in dogs and horses. One factor of note is that polysulfated glycosaminoglycans are heparin analogs, resulting in a transient prolonged partial thromboplastin time. Do not use this agent preoperatively or in cats with bleeding disorders; and do not use concurrently with NSAIDs that have potent antithromboxane activity.

**Acupuncture**

Acupuncture is another form of therapy or adjunctive therapy to consider. Some cats are excellent candidates and seem to respond favorably. While efficacy has been shown for a few conditions in humans, there is no solid scientific evidence at the time of writing that points to its efficacy in cats.²

**Client Education**

We must teach our clients (and ourselves and our teams) to be more aware of painful conditions in cats, to possibly slow the progression of degeneration (by using disease-modifying osteoarthritic agents), and to identify side effects of any prescribed medication. Clients should be told to stop medications and contact a clinic immediately if they notice:

- **Gastrointestinal side effects:** Inappetence, nausea, vomiting or hematemesis, lethargy
- **Renal failure:** Similar to gastrointestinal side effects, with possibly more severe lethargy, dehydration and, if severe, anuria.

---

**TABLE**

Categories of Analgesics Available for Use in Cats

<table>
<thead>
<tr>
<th>Category/Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid pure agonists</td>
</tr>
<tr>
<td>Morphine, hydromorphone, fentanyl, codeine, etc</td>
</tr>
<tr>
<td>Opioid partial agonists</td>
</tr>
<tr>
<td>Buprenorphine</td>
</tr>
<tr>
<td>Opioid agonist-antagonist</td>
</tr>
<tr>
<td>Butorphanol</td>
</tr>
<tr>
<td>NSAIDs*</td>
</tr>
<tr>
<td>Aspirin, carprofen, ketoprofen, meloxicam, tolmetin acid</td>
</tr>
<tr>
<td>Local anesthetics</td>
</tr>
<tr>
<td>Lidocaine, bupivicaine, carbocaine, mepivacaine, EMLA cream (eutectic mixture of lidocaine and prilocaine; astrazeneca.com)</td>
</tr>
<tr>
<td>Alpha-2 agonists</td>
</tr>
<tr>
<td>Xylazine, medetomidine</td>
</tr>
<tr>
<td>Chondroprotective agents</td>
</tr>
<tr>
<td>Glucosamine, chondroitin sulfate</td>
</tr>
<tr>
<td>Adjunctive agents</td>
</tr>
<tr>
<td>NMDA receptor antagonists [eg, ketamine, amantadine], gabapentin, amitryptiline, diazepam, acepromazine, corticosteroids [eg, prednisolone]</td>
</tr>
</tbody>
</table>

* Not approved for long-term use in cats in the U.S.

---

CS = chondroitin sulfate; DJD = degenerative joint disease; IRIS = International Renal Interest Society; NMDA = N-methyl d-aspartate; NSAID = nonsteroidal antiinflammatory drug; OA = osteoarthritis

---

NSAIDs

NSAIDs are useful preemptively or in combination with opioids for chronic pain. They must be used carefully, being mindful of the patient’s renal, hepatic, and coagulation status.
Adverse Effects
Of most concern is use of NSAIDs in patients predisposed to dehydration and the resulting effects on gastric mucosal health and renal function. NSAIDs can also negatively affect proteoglycan synthesis by cartilage; however, some NSAIDs (e.g., meloxicam and carprofen), when used at recommended doses, did not have this effect in in vitro studies. While it would ideal to use NSAIDs only in patients with optimal renal function, by optimizing hydration and dosing cautiously it is possible to enhance quality of life. Inform the client of possible side effects and use the lowest possible effective dose, never exceeding manufacturer recommendations.

Studies
Pharmacokinetic data are lacking for long-term use of NSAIDs in cats; there has been limited work done on the safety of chronic use or the metabolism of these drugs, with the exception of meloxicam. Meloxicam has been shown to undergo oxidative metabolism rather than glucuronidation, thus using a readily available hepatic pathway. As most NSAIDs have long half-lives in cats when compared with other species, a necessary precaution to avoid toxicity is to reduce the frequency of administration. In one study, cats were treated for 1 month with meloxicam. Clients felt that their cats were more willing to jump and the height of jumping increased during the study. Evaluation of the cats at the end of the month showed a significant reduction of gait stiffness. Metacam 0.5 mg/mL oral suspension (boehringer-ingelheim.com) has been granted a licence in the EU for the alleviation of inflammation and pain in chronic musculoskeletal disorders in cats. Pharmacokinetic studies as well as safety and efficacy studies have been performed to the satisfaction of the regulatory bodies. This is the first NSAID licensed for long-term use in cats.

Two studies have evaluated long-term safety of this agent in older cats; one concluded that it is safe, efficacious, and palatable for OA pain at 0.01 to 0.03 mg/kg PO Q 24 H for a mean treatment duration of 5.8 months; no deleterious effect on renal function was detected in cats studied. The second reviewed the medical records of cats over 7 years of age treated for a minimum of 6 months with a daily maintenance dose of 0.02 mg/kg meloxicam; it concluded that this dose does not hasten progression of renal disease in aged cats or aged cats with preexistent stable IRIS stage I to III renal disease. Studies conducted that this dose does not hasten progression of renal disease in aged cats or aged cats with preexistent stable IRIS stage I to III renal disease. Studies conducted that this dose does not hasten progression of renal disease in aged cats or aged cats with preexistent stable IRIS stage I to III renal disease.

Administration
Of the NSAIDs available, meloxicam is approved for use in cats in the U.S.; however, the oral suspension is only approved for use in cats in the EU, Canada, and Australia. Carprofen is not approved for cats in the U.S., but is approved in the United Kingdom. The dosage recommendations (label doses for the EU) are:
- Meloxicam (0.5 mg/mL oral suspension; for the alleviation of inflammation and pain in chronic musculoskeletal disorders): 0.1 mg/kg on the first day followed by 0.05 mg/kg PO Q 24 H.
- Carprofen: 4 mg/kg SC, once only

The key to safe chronic NSAID administration in cats is the use of the smallest effective dose and avoiding use, or using much lower doses, in cats with renal disease. Ensure the patient is hydrated and give the NSAID with food. In most cases, NSAIDs are most effective when used in conjunction with other treatment modalities.

Opioids
Opioids are suitable to treat moderate to severe acute pain or mild to severe chronic pain. Because of possible adverse side effects (euphoria, constipation, inappetence) their use is best reserved for palliative hospice care, to treat breakthrough pain, or for comfort during diagnostic testing. In the older patient or one with impaired renal or hepatic function, additional doses of opioids result in prolongation of effect. Opioids should not be used in a vomiting patient because of risk for tentorial herniation.

The advantages of the pure opioid agonists in older cats include:
- Safety
- Lack of “ceiling effect,” allowing dosing to effect
- Partial-to-complete reversibility if needed.

Partial agonists, or agonist antagonists, have a ceiling effect, resulting in their inability to provide additional analgesia and a possible reduction of analgesia; they may also cause sedation, which may be misinterpreted as comfort. These opioids are suitable for mild to moderate acute and chronic pain. Buccal buprenorphine, used on an intermittent basis, is very useful for breakthrough pain.

Corticosteroids
Corticosteroids are an option for cats with extremely fragile kidneys. However, they should be used as a last resort due to their ability to damage cartilage. They are not without risk to gastrointestinal health as well as the plethora of other well known possible adverse reactions. In our practice,

CONTINUES
we explain the risks to the client and discuss quality versus quantity of life, which usually results in choosing analgesia over risk-free pain.

Multimodal Therapy
Multimodal therapy offers the advantage of reducing the dose of each agent as well as affecting different parts of the nociceptive pathway:
- Pure opioids block transmission in the ascending neurons and also affect the receptors in the brain.
- Agonist antagonists block only spinal neuron receptors.
- NSAIDs affect the release of inflammatory mediators at the site of injury, which is why they are integral to preemptive analgesia.
- Local anesthesia prevents stimulation of nerves.
- NMDA (N-methyl d-aspartate) receptor antagonists are used adjunctively to improve pain control and help modulate or prevent “central sensitization,” an amplification of the intensity of pain caused by repeated stimulation of nerve fibers and alterations in the CNS response.

FOLLOW-UP
Patient Monitoring
- Patients on NSAIDs should have their renal parameters and CBC monitored 2 weeks then 1 month after beginning NSAID administration. For the older cat, repeated evaluation every 3 to 4 months may be warranted.
- Perform physical examination that includes evaluating weight change and body condition.
- Teach clients to assess hydration by checking skin elasticity and possibly mucous membrane moisture. In addition, if the feces are hard and shaped in pieces rather than logs, the patient is dehydrated.

Course
Therapy for DJD will be long term and may need to be modified to suit progression of arthritis or concurrent disorder.

At-Home Treatment
- Oral or injectable medication plus subcutaneous fluids if needed
- Environmental modifications may be needed as the cat becomes less able to navigate. Litter boxes may need to be modified so that the edge isn’t as high. A larger box may eliminate the problem of urinating or defecating over the rim of the box.

IN GENERAL
Relative Cost
- Physical examination and radiographs: $$$
- Minimum database for the older cat (CBC with differential, chemistry panel, urinalysis, blood pressure evaluation): $$$
- NSAID therapy (annual cost): $
- Opioid therapy (annual cost): $$
- Disease-modifying osteoarthritic agents (annual cost): $$$
- Acupuncture (annual cost): $$-$ $$$ (extremely variable)

Prognosis
Fair to guarded depending on concurrent diseases and potential complications from therapy. DJD usually remains stable for long periods of time.

Future Considerations
Although not currently available, dietary therapy designed to address gene expression should be forthcoming.

See Aids & Resources, back page, for references and suggested reading.

CNS = central nervous system; DJD = degenerative joint disease; NMDA = N-methyl d-aspartate;
NSAID = nonsteroidal antiinflammatory drug; OA = osteoarthritis

Cost Key
$ = < $100
$$ = $100–$250
$$ = $250–$500
$$$ = $500–$1000
$$$$ = > $1000